Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-30
2011-08-30
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S233200, C544S287000, C544S284000
Reexamination Certificate
active
08008311
ABSTRACT:
Quinazolinones of formulae (a, b, c and d) are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
REFERENCES:
patent: 3322756 (1967-05-01), Ruschig et al.
patent: 4992550 (1991-02-01), Hughes
patent: 5264439 (1993-11-01), Greenlee et al.
patent: 5444061 (1995-08-01), Bisset et al.
patent: 5561133 (1996-10-01), Bisset et al.
patent: 5753664 (1998-05-01), Aono et al.
patent: 5756502 (1998-05-01), Padia
patent: 5783577 (1998-07-01), Houghten et al.
patent: 5869665 (1999-02-01), Padia
patent: 6136812 (2000-10-01), Chenard et al.
patent: 6518277 (2003-02-01), Sadhu et al.
patent: 6545004 (2003-04-01), Finer et al.
patent: 6545005 (2003-04-01), Baxter et al.
patent: 6559160 (2003-05-01), Schall et al.
patent: 6562831 (2003-05-01), Finer et al.
patent: 6596497 (2003-07-01), Jiang et al.
patent: 6596723 (2003-07-01), Watkins et al.
patent: 6613798 (2003-09-01), Porter et al.
patent: 6627755 (2003-09-01), Chenard et al.
patent: 6630479 (2003-10-01), Finer et al.
patent: 6753428 (2004-06-01), Bergnes et al.
patent: 6794379 (2004-09-01), Medina et al.
patent: 6831085 (2004-12-01), Bergnes et al.
patent: 7009049 (2006-03-01), Bergnes et al.
patent: 7105668 (2006-09-01), Bergnes et al.
patent: 7161002 (2007-01-01), Bergnes et al.
patent: 7230000 (2007-06-01), Finer et al.
patent: 7294634 (2007-11-01), Finer et al.
patent: 7589098 (2009-09-01), Finer et al.
patent: 2001/0046997 (2001-11-01), Abraham et al.
patent: 2002/0169159 (2002-11-01), Medina et al.
patent: 2003/0055054 (2003-03-01), Medina et al.
patent: 2003/0091946 (2003-05-01), Uehira et al.
patent: 2003/0119854 (2003-06-01), Schall et al.
patent: 2003/0130293 (2003-07-01), Bamdad
patent: 2003/0139398 (2003-07-01), Hoekstra et al.
patent: 2003/0139457 (2003-07-01), Baxter et al.
patent: 2003/0144350 (2003-07-01), Stevenson et al.
patent: 2003/0166933 (2003-09-01), Bergnes et al.
patent: 2003/0171387 (2003-09-01), Sun et al.
patent: 2003/0195211 (2003-10-01), Sadhu et al.
patent: 2003/0220338 (2003-11-01), Watkins et al.
patent: 2003/0220356 (2003-11-01), Ibrahim et al.
patent: 2004/0023996 (2004-02-01), Finer et al.
patent: 2004/0067969 (2004-04-01), Bergnes et al.
patent: 2004/0077667 (2004-04-01), Matsuoka et al.
patent: 2004/0192913 (2004-09-01), Bergnes et al.
patent: 2004/0254203 (2004-12-01), Finer et al.
patent: 2005/0059823 (2005-03-01), McNaughton-Smith et al.
patent: 2005/0152940 (2005-07-01), Hezi-Yamit et al.
patent: 2005/0187232 (2005-08-01), Finer et al.
patent: 2005/0209254 (2005-09-01), Wang et al.
patent: 2005/0282834 (2005-12-01), Malik et al.
patent: 2006/0041130 (2006-02-01), Bergnes et al.
patent: 2007/0254902 (2007-11-01), Finer et al.
patent: 2008/0182864 (2008-07-01), Finer et al.
patent: B12617/88 (1988-09-01), None
patent: 0 056 637 (1982-07-01), None
patent: 0 286 813 (1988-02-01), None
patent: 0 509 643 (1992-10-01), None
patent: 0 884 310 (1998-12-01), None
patent: 0 884 316 (1998-12-01), None
patent: 0 900 568 (1999-03-01), None
patent: 0 903 344 (1999-03-01), None
patent: WO 93/19051 (1993-09-01), None
patent: WO 95/16682 (1995-06-01), None
patent: WO 97/10221 (1997-03-01), None
patent: WO 98/26664 (1998-06-01), None
patent: WO 99/42456 (1999-08-01), None
patent: WO 01/16114 (2001-03-01), None
patent: WO 01/19800 (2001-03-01), None
patent: WO 01/23364 (2001-04-01), None
patent: WO 01/23365 (2001-04-01), None
patent: WO 01/25235 (2001-04-01), None
patent: WO 01/30768 (2001-05-01), None
patent: WO 01/70737 (2001-09-01), None
patent: WO 01/74344 (2001-10-01), None
patent: WO 01/81346 (2001-11-01), None
patent: WO 01/98278 (2001-12-01), None
patent: WO 02/08224 (2002-01-01), None
patent: WO 02/30462 (2002-04-01), None
patent: WO 02/083143 (2002-10-01), None
patent: WO 02/094790 (2002-11-01), None
patent: WO 03/020279 (2003-03-01), None
patent: WO 03/020280 (2003-03-01), None
patent: WO 03/027234 (2003-04-01), None
patent: WO 03/043961 (2003-05-01), None
patent: WO 03/043995 (2003-05-01), None
patent: WO 03/049527 (2003-06-01), None
patent: WO 03/049679 (2003-06-01), None
patent: WO 03/050064 (2003-06-01), None
patent: WO 03/050122 (2003-06-01), None
patent: WO 03/070701 (2003-08-01), None
patent: WO 03/076418 (2003-09-01), None
patent: WO 03/084544 (2003-10-01), None
patent: WO 03/106435 (2003-12-01), None
patent: WO 2004/020599 (2004-03-01), None
patent: WO 2005/123083 (2005-12-01), None
Ager et al., “Synthesis and Central Nervous System Activity of Quinazolones Related to 2-Methyl-3-(o-tolyl)-4(3H) quinazolone (Methaqualone),”J. Med. Chem. 20(3): 379-386 (1977).
Ager et al., Chemical Abstracts, vol. 86, Abstract No. 83505 (1977).
Ahmad et al., “Monoamine oxidase Inhibitory Activity of 4 (3H)-Quinazolinones of Dopamine,”Indian J. of Pharm. Sci. 126-127 (1979).
Bergman et al., “Synthesis of Chrysogine, a Metabolite ofPenicillium chrysogenumand some related 2-substituted 4-(3H)-Quinazolinones,”Tetrahedron46: 1295-1310 (1990).
Bocskei, Z. et al., “Two Antithrombotic Quinazolone Derivatives.,”Acta Crystallogr., Sect. C: Cryst. Struct. Commun. C51(4): 723-726 (1995).
Chaurasia et al., Chemical Abstracts, vol. 96, Abstract No. 6681 (1982).
CHEMCATS Copyright 2001 ACS, 1998:596123 CHEMCATS, Maybridge, Apr. 3, 2000. DP 01489, “N2-(3-pyridylmethyl)-4-oxo-3,4-dihydroquinazoline-2-carboxamide,” 190437-46-8, Chemical Library.
Chenard et al,, “Quinazolin-4-one α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonists: Structure-Activity Relationship of the C-2 Side Chain Tether,”J. Med. Chem44:1710-1717 (2001).
Coleman et al., “Inhibitors of the mitotic kinesin spindle protein,”Expert Opin. Ther. Patents14(12): 1659-1667 (2004).
Commercially available from ComGenex, Sep. 16, 1999.
“Cytokinetics and GlaxoSmithKline Announce Seven Presentations At The 2002 Annual Meeting Of The American Association for Cancer Research—Broad Alliance to Generate First IND in 2002,”Press Release, Cytokinetics, Inc., 4 pages, (Apr. 8, 2002).
“Cytokinetics Announces Clinical and Non-Clinical Data on Ispinesib to be Presented at the 2005 AACR-NCI-EORTC International Meeting-Data from Two Phase lb Combination Trials to be Presented,”Press Release, Cytokinetics, Inc., 3 pages, (Nov. 10, 2005).
“Cytokinetics Announces Clinical and Non-Clinical Results on Ispinesib at the 2005 AACR-NCI-EORTC International Meeting-Data from Two Phase lb Combination Trials Presented,”Press Release, Cytokinetics, Inc., 4 pages, (Nov. 17, 2005).
“Cytokinetics Announces Interim Phase II Breast Cancer data for Ispinesib to be presented at San Antonio Breast Cancer Symposium,”Press Release, Cytokinetics, Inc., 3 pages, (Dec. 1, 2005).
“Cytokinetics Announces Phase I Results for SB-715992 to be Presented at the 2004 Annual Meeting Of The American Society of Clinical Oncology,”Press Release, Cytokinetics, Inc., 2 pages, (Jun. 2, 2004).
“Cytokinetics Announces Phase I Results for the SB-715992 presented at the 2004 Annual Meeting Of The American Society of Clinical Oncology—Safety and Tolerability Profile of the SB-715992 Supports Initiation of Broad Phase II Program,”Press Release, Cytokinetics, Inc., 3 pages, (Jun. 7, 2004).
“Cytokinetics Announces Presentation of Ispinesib data at San Antonio Breast Cancer Symposium—Anticancer Activity Supportive of Continuation of Phase II Clinical Trial,”Press Release, Cytokinetics, Inc., 3 pages, (Dec. 8, 2005).
“Cytokinetics Announces the Initiation of a Broad Phase II Clinical Trials Program in Oncology for SB-715992-Milestone Payment Triggered under Collaboration with GlaxoSmithKline,”Press Release, Cytokinetics, Inc., 3 pages, (Jan. 14, 2004).
“Cytokinetics Announces the Initiation of an Additional Phase II Clinical Trial for Lead Cancer Drug Candidate—Company Provides Update on Clinical Trials Program for SB-715992 and SB-743921,”Press Release, Cytokinetics, Inc., 4 pages, (Dec.
Bergnes Gustave
Chabala John C.
Feng Bainian
Finer Jeffrey T.
Smith Whitney W.
Cytokinetics Inc.
Fetterolf Brandon
Foley & Lardner LLP
Gembeh Shirley V
LandOfFree
Methods and compostions utilizing quinazolinones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compostions utilizing quinazolinones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compostions utilizing quinazolinones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2730089